前立腺がん治療薬開発の世界市場：ファーストインクラス革新の特定と商業化...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 4
2.1 Active Pipeline Reflects Large Market with Significant Unmet Needs 4
2.2 Market Landscape to Grow in Diversity over Coming Decade 4
2.3 Deals Landscape Presents Significant Investment Opportunities for First-in-Class Products 4

3 The Case for Innovation in Prostate Cancer 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 9

4 Clinical and Commercial Landscape 10
4.1 Disease Overview 10
4.1.1 Epidemiology 10
4.1.2 Etiology 11
4.1.3 Disease Pathophysiology 12
4.1.4 Disease Symptoms 14
4.1.5 Disease Staging and Diagnosis 14
4.1.6 Treatment 16
4.2 Overview of Marketed Products 19
4.2.1 Hormonal Therapies 19
4.2.2 Chemotherapy 20
4.2.3 Therapeutic Vaccines 20
4.2.4 Targeted Therapies (Second Generation Anti-androgens) 21
4.2.5 Bone Metastasis Treatments 21

5 Assessment of Pipeline Product Innovation 22
5.1 Prostate Cancer Pipeline by Molecule Type, Phase and Therapeutic Target 22
5.2 Comparative Distribution of Programs between the Prostate Cancer Market and Pipeline by Molecular Target 28
5.3 First-in-Class Pipeline Programs Targeting Novel Molecule Targets 28

6 Signaling Network, Disease Causation and Innovation Alignment 35
6.1 The Complexity of Signaling Networks in Oncology 35
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 36
6.3 First-in-class Target Matrix Assessment 38

7 First-in-Class Target and Pipeline Program Evaluation 42
7.1 Pipeline Programs Targeting Human Double Minute 2 42
7.1.1 Overview of Pipeline Programs Targeting MDM2 44
7.2 Pipeline Programs Targeting AKT1 44
7.2.1 Overview of Pipeline Programs Targeting AKT1 46
7.3 Pipeline Programs Targeting Tumor Protein p53 46
7.3.1 Overview of Pipeline Programs Targeting p53 47
7.4 Pipeline Programs Targeting Mitogen-Activated Protein Kinase 47
7.4.1 Overview of Pipeline Programs Targeting MAPK 49
7.5 Pipeline Programs Targeting Specificity Protein 1 49
7.5.1 Overview of Pipeline Programs Targeting Specificity Protein 1 52
7.6 Pipeline Programs Targeting X-linked Inhibitor of Apoptosis Protein 52
7.6.1 Overview of Pipeline Programs Targeting X-linked Inhibitor of Apoptosis Protein 53
7.7 Pipeline Programs Targeting Hypoxia-Inducible Factor 1 53
7.7.1 Overview of Pipeline Programs Targeting Hypoxia-Inducible Factor 1 55
7.8 Pipeline Programs Targeting Galectin-3 55
7.8.1 Overview of Pipeline Programs Targeting Galectin-3 56
7.9 Pipeline Programs Targeting Prostate Specific Membrane Antigen 57
7.9.1 Overview of Pipeline Programs Targeting Prostate Specific Membrane Antigen 59
7.10 Pipeline Programs Targeting Aurora Kinase 59
7.10.1 Overview of Pipeline Programs Targeting Aurora Kinase 61
7.11 Conclusion 62

8 Deals and Strategic Consolidations 63
8.1 Industry-wide First-in-Class Deals 63
8.2 Licensing Deals 65
8.3 Co-developments 68
8.4 First-in-Class Programs not Involved in Licensing or Co-Development Deals 70

9 Appendix 75
9.1 References 75
9.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration Tables 82
9.3 Abbreviations 89
9.4 Expert Panel Validation 90
9.5 Contact Us 91
9.6 Disclaimer 91